Increased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda
-
- Kyle D. Smith
- Department of Microbiology, University of Minnesota, Minneapolis, Minnesota, USA
-
- Beatrice Achan
- Department of Medical Microbiology, Makerere University, Kampala, Uganda
-
- Kathy Huppler Hullsiek
- Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA
-
- Tami R. McDonald
- Department of Biology, St. Catherine University, St. Paul, Minnesota, USA
-
- Laura H. Okagaki
- Center for Integrated Fungal Research, North Carolina State University, Raleigh, North Carolina, USA
-
- Ali A. Alhadab
- Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, Minnesota, USA
-
- Andrew Akampurira
- Infectious Diseases Institute, Makerere University, Kampala, Uganda
-
- Joshua R. Rhein
- Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA
-
- David B. Meya
- Infectious Diseases Institute, Makerere University, Kampala, Uganda
-
- David R. Boulware
- Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA
-
- Kirsten Nielsen
- Department of Microbiology, University of Minnesota, Minneapolis, Minnesota, USA
書誌事項
- 公開日
- 2015-12
- 権利情報
-
- https://journals.asm.org/non-commercial-tdm-license
- DOI
-
- 10.1128/aac.01299-15
- 公開者
- American Society for Microbiology
この論文をさがす
説明
<jats:title>ABSTRACT</jats:title> <jats:p> Cryptococcal antigen screening is recommended among people living with AIDS when entering HIV care with a CD4 count of <100 cells/μl, and preemptive fluconazole monotherapy treatment is recommended for those with subclinical cryptococcal antigenemia. Yet, knowledge is limited of current antimicrobial resistance in Africa. We examined antifungal drug susceptibility in 198 clinical isolates collected from Kampala, Uganda, between 2010 and 2014 using the CLSI broth microdilution assay. In comparison with two previous studies from 1998 to 1999 that reported an MIC <jats:sub>50</jats:sub> of 4 μg/ml and an MIC <jats:sub>90</jats:sub> of 8 μg/ml prior to widespread human fluconazole and agricultural azole fungicide usage, we report an upward shift in the fluconazole MIC <jats:sub>50</jats:sub> to 8 μg/ml and an MIC <jats:sub>90</jats:sub> value of 32 μg/ml, with 31% of isolates with a fluconazole MIC of ≥16 μg/ml. We observed an amphotericin B MIC <jats:sub>50</jats:sub> of 0.5 μg/ml and an MIC <jats:sub>90</jats:sub> of 1 μg/ml, of which 99.5% of isolates (197 of 198 isolates) were still susceptible. No correlation between MIC and clinical outcome was observed in the context of amphotericin B and fluconazole combination induction therapy. We also analyzed <jats:named-content xmlns:xlink="http://www.w3.org/1999/xlink" content-type="genus-species" xlink:type="simple">Cryptococcus</jats:named-content> susceptibility to sertraline, with an MIC <jats:sub>50</jats:sub> of 4 μg/ml, suggesting that sertraline is a promising oral, low-cost, available, novel medication and a possible alternative to fluconazole. Although the CLSI broth microdilution assay is ideal to standardize results, limit human bias, and increase assay capacity, such assays are often inaccessible in low-income countries. Thus, we also developed and validated an assay that could easily be implemented in a resource-limited setting, with similar susceptibility results ( <jats:italic>P</jats:italic> = 0.52). </jats:p>
収録刊行物
-
- Antimicrobial Agents and Chemotherapy
-
Antimicrobial Agents and Chemotherapy 59 (12), 7197-7204, 2015-12
American Society for Microbiology